{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:48:20Z","timestamp":1793648900585,"version":"4.5.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While iron homeostasis in cancer cells is well-established, its role in mediating crosstalk between tumors and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells within the tumor microenvironment (TME) remains largely elusive. In this study, we compare iron levels across primary tissues populated by CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Contrary to the systemic iron deficiency commonly found in cancer patients, the TME exhibits marked iron enrichment compared to lymphatic fluid and peripheral blood, a phenomenon primarily attributed to tumor necrosis. However, this iron-overloaded TME is detrimental to CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, triggering their ferroptosis and dysfunction. Mechanistically, tumoral T cell receptor (TCR) hyperactivation and tumor-derived hepcidin cooperatively downregulate the iron exporter SLC40A1 in CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, leading to intracellular iron accumulation and ferroptosis. Both genetic restoration of SLC40A1 and iron chelation inhibit CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell ferroptosis and restore their cytotoxic activity, thereby suppressing tumor growth. Finally, to enhance chimeric antigen receptor T (CAR-T) cell adaptability to the iron-overloaded TME, we engineer SLC40A1-overexpressing CAR-T cells. These engineered cells resist ferroptosis induced by the TME and elicit potent anti-tumor immunity.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-73379-4","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:15:41Z","timestamp":1779462941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Iron overload in the tumor microenvironment induces CD8+ T cell ferroptosis and dysfunction"],"prefix":"10.1038","volume":"17","author":[{"given":"Zhenyu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8810-0393","authenticated-orcid":false,"given":"Huanpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0980-6521","authenticated-orcid":false,"given":"Yujing","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0780-5876","authenticated-orcid":false,"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6589-6827","authenticated-orcid":false,"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9599-9907","authenticated-orcid":false,"given":"Yingjie","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"73379_CR1","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/annonc\/mdt118","volume":"24","author":"H Ludwig","year":"2013","unstructured":"Ludwig, H., M\u00fcld\u00fcr, E., Endler, G. & H\u00fcbl, W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 24, 1886\u20131892 (2013).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"73379_CR2","doi-asserted-by":"publisher","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","volume":"29","author":"M Aapro","year":"2018","unstructured":"Aapro, M. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 29, iv96\u2013iv110 (2018).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"73379_CR3","doi-asserted-by":"crossref","unstructured":"Natalucci, V. et al. Cancer-related anemia: an integrated multitarget approach and lifestyle interventions. Nutrients 13, 482 (2021).","DOI":"10.3390\/nu13020482"},{"key":"73379_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104788","volume":"213","author":"F Miglietta","year":"2025","unstructured":"Miglietta, F. et al. Anaemia in cancer patients: advances and challenges in the era of precision oncology. Crit. Rev. Oncol. Hematol. 213, 104788 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"73379_CR5","doi-asserted-by":"crossref","unstructured":"Auerbach, M. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22, 1301\u20131307 (2004).","DOI":"10.1200\/JCO.2004.08.119"},{"key":"73379_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.leu.2404562","volume":"21","author":"M Hedenus","year":"2007","unstructured":"Hedenus, M. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21, 627\u2013632 (2007).","journal-title":"Leukemia"},{"key":"73379_CR7","doi-asserted-by":"crossref","unstructured":"Bastit, L. et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 26, 1611\u20131618 (2008).","DOI":"10.1200\/JCO.2006.10.4620"},{"key":"73379_CR8","doi-asserted-by":"crossref","unstructured":"Pedrazzoli, P. et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J. Clin. Oncol. 26, 1619\u20131625 (2008).","DOI":"10.1200\/JCO.2007.12.2051"},{"key":"73379_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ajh.21779","volume":"85","author":"M Auerbach","year":"2010","unstructured":"Auerbach, M. et al. Darbepoetin alfa 300 or 500 \u03bcg once every 3 weeks with or without intravenous Iron in patients with chemotherapy-induced anemia. Am. J. Hematol. 85, 655\u2013663 (2010).","journal-title":"Am. J. Hematol."},{"key":"73379_CR10","doi-asserted-by":"crossref","unstructured":"Buchrits, S., Itzhaki, O., Avni, T., Raanani, P. & Gafter-Gvili, A. Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. in J. Clin. Med. 11, 4156 (2022).","DOI":"10.3390\/jcm11144156"},{"key":"73379_CR11","doi-asserted-by":"publisher","first-page":"E133","DOI":"10.1002\/ajh.24013","volume":"90","author":"A Jaspers","year":"2015","unstructured":"Jaspers, A. et al. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. Am. J. Hematol. 90, E133\u2013E134 (2015).","journal-title":"Am. J. Hematol."},{"key":"73379_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.mehy.2017.12.011","volume":"110","author":"MJ Wilson","year":"2018","unstructured":"Wilson, M. J., Harlaar, J. J., Jeekel, J., Schipperus, M. & Zwaginga, J. J. Iron therapy as treatment of anemia: a potentially detrimental and hazardous strategy in colorectal cancer patients. Med. Hypotheses 110, 110\u2013113 (2018).","journal-title":"Med. Hypotheses"},{"key":"73379_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood.2019004017","volume":"136","author":"JA Gilreath","year":"2020","unstructured":"Gilreath, J. A. & Rodgers, G. M. How I treat cancer-associated anemia. Blood 136, 801\u2013813 (2020).","journal-title":"Blood"},{"key":"73379_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tips.2023.12.003","volume":"45","author":"Y-Y Zhang","year":"2024","unstructured":"Zhang, Y.-Y., Han, Y., Li, W.-N., Xu, R.-H. & Ju, H.-Q. Tumor iron homeostasis and immune regulation. Trends Pharmacol. Sci. 45, 145\u2013156 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"73379_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41580-023-00648-1","volume":"25","author":"B Galy","year":"2024","unstructured":"Galy, B., Conrad, M. & Muckenthaler, M. Mechanisms controlling cellular and systemic iron homeostasis. Nat. Rev. Mol. Cell Biol. 25, 133\u2013155 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"73379_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.canlet.2016.08.006","volume":"381","author":"B Wang","year":"2016","unstructured":"Wang, B. et al. EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1. Cancer Lett. 381, 331\u2013340 (2016).","journal-title":"Cancer Lett."},{"key":"73379_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbrc.2016.02.023","volume":"471","author":"SM Jeong","year":"2016","unstructured":"Jeong, S. M., Hwang, S. & Seong, R. H. Transferrin receptor regulates pancreatic cancer growth by modulating mitochondrial respiration and ROS generation. Biochem. Biophys. Res. Commun. 471, 373\u2013379 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"73379_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4257342","volume":"2022","author":"J Cao","year":"2022","unstructured":"Cao, J. et al. Aberrant expression TFR1\/CD71 in gastric cancer identifies a novel potential prognostic marker and therapeutic target. Evid. Based Complement. Alternat. Med. 2022, 4257342 (2022).","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"73379_CR19","doi-asserted-by":"crossref","unstructured":"Tesfay, L. et al. Hepcidin regulation in the prostate and its disruption in prostate cancer. 75, 2254-2263 (2015).","DOI":"10.1158\/0008-5472.CAN-14-2465"},{"key":"73379_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41419-019-1854-0","volume":"10","author":"Y Kong","year":"2019","unstructured":"Kong, Y. et al. Ferroportin downregulation promotes cell proliferation by modulating the Nrf2\u2013miR-17-5p axis in multiple myeloma. Cell Death Dis. 10, 624 (2019).","journal-title":"Cell Death Dis."},{"key":"73379_CR21","doi-asserted-by":"publisher","first-page":"8737","DOI":"10.18632\/aging.202685","volume":"13","author":"B Liu","year":"2021","unstructured":"Liu, B. et al. Downregulation of FPN1 acts as a prognostic biomarker associated with immune infiltration in lung cancer. Aging 13, 8737\u20138761 (2021).","journal-title":"Aging"},{"key":"73379_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","volume":"42","author":"K Roemhild","year":"2021","unstructured":"Roemhild, K. et al. Iron metabolism: pathophysiology and pharmacology. Trends Pharmacol. Sci. 42, 640\u2013656 (2021).","journal-title":"Trends Pharmacol. Sci."},{"key":"73379_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru, Q. et al. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct. Target. Ther. 9, 271 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"73379_CR24","doi-asserted-by":"crossref","unstructured":"Voss, K. et al. Elevated transferrin receptor impairs T cell metabolism and function in systemic lupus erythematosus. Sci. Immunol. 8, eabq0178 (2023).","DOI":"10.1126\/sciimmunol.abq0178"},{"key":"73379_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.immuni.2018.05.008","volume":"49","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Iron drives T helper cell pathogenicity by promoting RNA-binding protein PCBP1-mediated proinflammatory cytokine production. Immunity 49, 80\u201392.e87 (2018).","journal-title":"Immunity"},{"key":"73379_CR26","doi-asserted-by":"crossref","unstructured":"Gao, X. et al. Iron-dependent epigenetic modulation promotes pathogenic T cell differentiation in lupus. J. Clin. Investig. 132, e152345 (2022).","DOI":"10.1172\/JCI152345"},{"key":"73379_CR27","doi-asserted-by":"crossref","unstructured":"Scindia, Y., Mehrad, B. & Morel, L. Labile iron accumulation augments T follicular helper cell differentiation. J. Clin. Investig. 132, e159472 (2022).","DOI":"10.1172\/JCI159472"},{"key":"73379_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2318420121","volume":"121","author":"A Kumar","year":"2024","unstructured":"Kumar, A. et al. Iron regulates the quiescence of naive CD4 T cells by controlling mitochondria and cellular metabolism. Proc. Natl. Acad. Sci. USA 121, e2318420121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73379_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.999","volume":"12","author":"Y Lai","year":"2022","unstructured":"Lai, Y. et al. Iron controls T helper cell pathogenicity by promoting glucose metabolism in autoimmune myopathy. Clin. Transl. Med. 12, e999 (2022).","journal-title":"Clin. Transl. Med."},{"key":"73379_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637809","volume":"12","author":"C Pfeifhofer-Obermair","year":"2021","unstructured":"Pfeifhofer-Obermair, C. et al. Regulation of Th1 T cell differentiation by iron via upregulation of T cell immunoglobulin and mucin-containing protein-3 (TIM-3). Front Immunol. 12, 637809 (2021).","journal-title":"Front Immunol."},{"key":"73379_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3537471","volume":"2018","author":"SY Lee","year":"2018","unstructured":"Lee, S. Y. et al. Regulation of tumor progression by programmed necrosis. Oxid. Med. Cell. Longev. 2018, 3537471 (2018).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"73379_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.trecan.2021.09.003","volume":"8","author":"J Yan","year":"2022","unstructured":"Yan, J., Wan, P., Choksi, S. & Liu, Z.-G. Necroptosis and tumor progression. Trends Cancer 8, 21\u201327 (2022).","journal-title":"Trends Cancer"},{"key":"73379_CR33","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.bbabio.2006.06.014","volume":"1757","author":"N Festjens","year":"2006","unstructured":"Festjens, N., Vanden Berghe, T. & Vandenabeele, P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim. Biophys. Acta (BBA) Bioenerg. 1757, 1371\u20131387 (2006).","journal-title":"Biochim. Biophys. Acta (BBA) Bioenerg."},{"key":"73379_CR34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1415","volume":"4","author":"J Vakkila","year":"2004","unstructured":"Vakkila, J. & Lotze, M. T. Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 4, 641\u2013648 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"73379_CR35","doi-asserted-by":"crossref","unstructured":"Adrover, J.M. et al. Neutrophils drive vascular occlusion, tumour necrosis and metastasis. Nature 645, 484\u2013495 (2025).","DOI":"10.1038\/s41586-025-09278-3"},{"key":"73379_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273\u2013285 (2017).","journal-title":"Cell"},{"key":"73379_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88 (2020).","journal-title":"Cell Death Dis."},{"key":"73379_CR38","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell, B. R. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401\u20132421 (2022).","journal-title":"Cell"},{"key":"73379_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41422-020-0355-0","volume":"30","author":"J Qian","year":"2020","unstructured":"Qian, J. et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 30, 745\u2013762 (2020).","journal-title":"Cell Res."},{"key":"73379_CR40","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114123","volume":"13","author":"F Uhlitz","year":"2021","unstructured":"Uhlitz, F. et al. Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer. EMBO Mol. Med. 13, e14123 (2021).","journal-title":"EMBO Mol. Med"},{"key":"73379_CR41","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1002\/cam4.2113","volume":"8","author":"Q Song","year":"2019","unstructured":"Song, Q. et al. Dissecting intratumoral myeloid cell plasticity by single-cell RNA-seq. Cancer Med. 8, 3072\u20133085 (2019).","journal-title":"Cancer Med."},{"key":"73379_CR42","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","volume":"3","author":"B Dong","year":"2020","unstructured":"Dong, B. et al. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer. Commun. Biol. 3, 778 (2020).","journal-title":"Commun. Biol."},{"key":"73379_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108978","volume":"35","author":"HQ Dinh","year":"2021","unstructured":"Dinh, H. Q. et al. Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube. Cell Rep. 35, 108978 (2021).","journal-title":"Cell Rep."},{"key":"73379_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41587-020-00795-2","volume":"39","author":"R Gao","year":"2021","unstructured":"Gao, R. et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat. Biotechnol. 39, 599\u2013608 (2021).","journal-title":"Nat. Biotechnol."},{"key":"73379_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00776-9","volume":"12","author":"W Lin","year":"2020","unstructured":"Lin, W. et al. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Med. 12, 80 (2020).","journal-title":"Genome Med."},{"key":"73379_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat. Cell Biol. 23, 87\u201398 (2021).","journal-title":"Nat. Cell Biol."},{"key":"73379_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27322-4","volume":"13","author":"H Song","year":"2022","unstructured":"Song, H. et al. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat. Commun. 13, 141 (2022).","journal-title":"Nat. Commun."},{"key":"73379_CR48","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","volume":"50","author":"R Zilionis","year":"2019","unstructured":"Zilionis, R. et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50, 1317\u20131334.e1310 (2019).","journal-title":"Immunity"},{"key":"73379_CR49","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442\u2013459.e429 (2020).","journal-title":"Cell"},{"key":"73379_CR50","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1091\/mbc.e07-01-0060","volume":"18","author":"I De Domenico","year":"2007","unstructured":"De Domenico, I. et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol. Biol. Cell 18, 2569\u20132578 (2007).","journal-title":"Mol. Biol. Cell"},{"key":"73379_CR51","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cmet.2012.03.018","volume":"15","author":"B Qiao","year":"2012","unstructured":"Qiao, B. et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 15, 918\u2013924 (2012).","journal-title":"Cell Metab."},{"key":"73379_CR52","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood.2020008986","volume":"138","author":"L Jiang","year":"2021","unstructured":"Jiang, L. et al. RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation. Blood 138, 689\u2013705 (2021).","journal-title":"Blood"},{"key":"73379_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrg3645","volume":"15","author":"NT Ingolia","year":"2014","unstructured":"Ingolia, N. T. Ribosome profiling: new views of translation, from single codons to genome scale. Nat. Rev. Genet. 15, 205\u2013213 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"73379_CR54","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrm4069","volume":"16","author":"GA Brar","year":"2015","unstructured":"Brar, G. A. & Weissman, J. S. Ribosome profiling reveals the what, when, where and how of protein synthesis. Nat. Rev. Mol. Cell Biol. 16, 651\u2013664 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"73379_CR55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2016.02.066","volume":"165","author":"NT Ingolia","year":"2016","unstructured":"Ingolia, N. T. Ribosome footprint profiling of translation throughout the genome. Cell 165, 22\u201333 (2016).","journal-title":"Cell"},{"key":"73379_CR56","doi-asserted-by":"crossref","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","DOI":"10.1126\/science.abe6474"},{"key":"73379_CR57","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281.e1224 (2019).","journal-title":"Cell"},{"key":"73379_CR58","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"73379_CR59","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"73379_CR60","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","volume":"179","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 179, 829\u2013845.e820 (2019).","journal-title":"Cell"},{"key":"73379_CR61","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes t cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997.e924 (2018).","journal-title":"Cell"},{"key":"73379_CR62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-020-2668-z","volume":"586","author":"CB Billesb\u00f8lle","year":"2020","unstructured":"Billesb\u00f8lle, C. B. et al. Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms. Nature 586, 807\u2013811 (2020).","journal-title":"Nature"},{"key":"73379_CR63","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1038\/emm.2017.273","volume":"50","author":"D Vela","year":"2018","unstructured":"Vela, D. & Vela-Gaxha, Z. Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications. Exp. Mol. Med. 50, e436\u2013e436 (2018).","journal-title":"Exp. Mol. Med."},{"key":"73379_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.963096","volume":"12","author":"T Dong","year":"2022","unstructured":"Dong, T. et al. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. Front. Oncol. 12, 963096 (2022).","journal-title":"Front. Oncol."},{"key":"73379_CR65","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/asheducation-2017.1.265","volume":"2017","author":"AT Taher","year":"2017","unstructured":"Taher, A. T. & Saliba, A. N. Iron overload in thalassemia: different organs at different rates. Hematology 2017, 265\u2013271 (2017).","journal-title":"Hematology"},{"key":"73379_CR66","doi-asserted-by":"crossref","unstructured":"Hider, R.C. & Hoffbrand, A.V.J.N.E.J.o.M. The role of deferiprone in iron chelation. N. Engl. J. Med. 379, 2140\u201350 (2018).","DOI":"10.1056\/NEJMra1800219"},{"key":"73379_CR67","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00262-020-02838-8","volume":"70","author":"H Chen","year":"2021","unstructured":"Chen, H. et al. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors. Cancer Immunol. Immunother. 70, 2059\u20132071 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"73379_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003737","volume":"10","author":"C Huanpeng","year":"2022","unstructured":"Huanpeng, C. et al. Delivery of CD47 blocker SIRP\u03b1-Fc by CAR-T cells enhances antitumor efficacy. J. Immunother. Cancer 10, e003737 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"73379_CR69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","volume":"585","author":"JM Ubellacker","year":"2020","unstructured":"Ubellacker, J. M. et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585, 113\u2013118 (2020).","journal-title":"Nature"},{"key":"73379_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60204-7","volume":"16","author":"MR Teh","year":"2025","unstructured":"Teh, M. R. et al. Iron deficiency causes aspartate-sensitive dysfunction in CD8+ T cells. Nat. Commun. 16, 5355 (2025).","journal-title":"Nat. Commun."},{"key":"73379_CR71","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/annonc\/mds112","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro, M., \u00d6sterborg, A., Gasc\u00f3n, P., Ludwig, H. & Beguin, Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann. Oncol. 23, 1954\u20131962 (2012).","journal-title":"Ann. Oncol."},{"key":"73379_CR72","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00508-015-0842-3","volume":"127","author":"H Ludwig","year":"2015","unstructured":"Ludwig, H. et al. Iron metabolism and iron supplementation in cancer patients. Wien. Klinische Wochenschr. 127, 907\u2013919 (2015).","journal-title":"Wien. Klinische Wochenschr."},{"key":"73379_CR73","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/17474086.2024.2375265","volume":"17","author":"GM Rodgers","year":"2024","unstructured":"Rodgers, G. M. Update on iron supplementation in patients with cancer-related anemia. Expert Rev. Hematol. 17, 505\u2013514 (2024).","journal-title":"Expert Rev. Hematol."},{"key":"73379_CR74","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1040-8428(01)00218-9","volume":"42","author":"DR Richardson","year":"2002","unstructured":"Richardson, D. R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol.\/Hematol. 42, 267\u2013281 (2002).","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"73379_CR75","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.bbagen.2008.04.003","volume":"1790","author":"DR Richardson","year":"2009","unstructured":"Richardson, D. R., Kalinowski, D. S., Lau, S., Jansson, P. J. & Lovejoy, D. B. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim. Biophys. Acta (BBA) Gen. Subj. 1790, 702\u2013717 (2009).","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"key":"73379_CR76","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10534-018-0123-5","volume":"31","author":"L-L Cao","year":"2018","unstructured":"Cao, L.-L. et al. Iron chelation inhibits cancer cell growth and modulates global histone methylation status in colorectal cancer. BioMetals 31, 797\u2013805 (2018).","journal-title":"BioMetals"},{"key":"73379_CR77","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/cas.14607","volume":"112","author":"K Komoto","year":"2021","unstructured":"Komoto, K. et al. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine. Cancer Sci. 112, 410\u2013421 (2021).","journal-title":"Cancer Sci."},{"key":"73379_CR78","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1158\/2159-8290.CD-23-1451","volume":"14","author":"TA Sandoval","year":"2024","unstructured":"Sandoval, T. A. et al. Iron chelation therapy elicits innate immune control of metastatic ovarian cancer. Cancer Discov. 14, 1901\u20131921 (2024).","journal-title":"Cancer Discov."},{"key":"73379_CR79","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/2326-6066.CIR-23-0739","volume":"12","author":"S Porte","year":"2024","unstructured":"Porte, S. et al. Iron boosts antitumor type 1 T-cell responses and anti-PD1 immunotherapy. Cancer Immunol. Res. 12, 1252\u20131267 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"73379_CR80","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41590-021-00996-0","volume":"22","author":"Y Yao","year":"2021","unstructured":"Yao, Y. et al. Selenium\u2013GPX4 axis protects follicular helper T cells from ferroptosis. Nat. Immunol. 22, 1127\u20131139 (2021).","journal-title":"Nat. Immunol."},{"key":"73379_CR81","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.immuni.2024.08.003","volume":"57","author":"Y Ping","year":"2024","unstructured":"Ping, Y. et al. PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis. Immunity 57, 2122\u20132139.e2129 (2024).","journal-title":"Immunity"},{"key":"73379_CR82","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"73379_CR83","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao, P. et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40, 365\u2013378 e366 (2022).","journal-title":"Cancer Cell"},{"key":"73379_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002723","volume":"9","author":"K Kedar","year":"2021","unstructured":"Kedar, K., Hany, E., Christine, H. C. & Daniel, A.-D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J. Immunother. Cancer 9, e002723 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"73379_CR85","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759\u20131776 (2021).","journal-title":"Br. J. Cancer"},{"key":"73379_CR86","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665\u2013679 (2025).","journal-title":"Cancer Cell"},{"key":"73379_CR87","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B. & Rodriguez, A. CAR-T therapies in solid tumors: opportunities and challenges. Curr. Oncol. Rep. 25, 479\u2013489 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"73379_CR88","doi-asserted-by":"publisher","first-page":"e3427","DOI":"10.21769\/BioProtoc.3427","volume":"9","author":"MR Sullivan","year":"2019","unstructured":"Sullivan, M. R., Lewis, C. A. & Muir, A. Isolation and quantification of metabolite levels in murine tumor interstitial fluid by LC\/MS. Bio-Protoc. 9, e3427 (2019).","journal-title":"Bio-Protoc."},{"key":"73379_CR89","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jss.2020.11.004","volume":"260","author":"B Banan","year":"2021","unstructured":"Banan, B. et al. Intestinal lymph collection via cannulation of the mesenteric lymphatic duct in mice. J. Surg. Res. 260, 399\u2013408 (2021).","journal-title":"J. Surg. Res."},{"key":"73379_CR90","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang, S. et al. Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic acids Res. 53, D1670\u2013d1676 (2025).","journal-title":"Nucleic acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73379-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73379-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73379-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:02:15Z","timestamp":1784743335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73379-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73379"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73379-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent application related to the SLC40A1 overexpression CAR-T therapy presented in this article has been submitted by Guangzhou National Laboratory (Engineered T cell, method of constructing, and applications; Chinese patent application No. 2025118135868, under preliminary examination; PCT application No. PCT\/CN2025\/139780, filed). Y.B., Z.L., and H.C. are listed as inventors. The authors declare no other competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6754"}}